S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PGEN · Precigen, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$6.60
-0.24
(-3.44%)
● At close: October 21 at 4:00:00 PM EDT
$6.53
-0.07
(-1.06%)
Overnight:
8:19:50 PM EDT
DAY'S RANGE
$6.60
$6.58
$6.92
52-WEEK RANGE
$6.60
$3.04
$8.98
What's happening
- PGEN is down 3.44% today, trading at $6.60. — Live quote
- Volume today (1,652,488) is well below its 3-month average of 5,063,770. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.05 actual vs. $-0.01 estimated (+467.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 6
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PGEN
+63.40%
vs S&P 500
+50.62%
1-YEAR RETURN
PGEN
+73.35%
vs S&P 500
+58.79%
6-MONTH RETURN
PGEN
+72.91%
3-MONTH RETURN
PGEN
+24.41%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.05
Est. $-0.01
BEAT +467.6%
2026-04-26 (Q1 2026)
$-0.02
Est. $-0.03
BEAT +38.7%
2026-01-26 (Q4 2025)
$-0.07
Est. $-0.09
BEAT +17.6%
2025-10-26 (Q3 2025)
$-1.06
Est. $-0.10
MISS -993.9%
Valuation Measures & Ratios
Enterprise Value4$2.53B
Forward P/E514.31
PEG Ratio6-0.04
Price / Sales (TTM1)28.57
Price / Book746.63
EV4 / Revenue29.48
EV4 / EBITDA—
Profit Margin-183.98%
Operating Margin-46.08%
Return on Equity (ROE8)-498.32%
Return on Assets (ROA9)-99.23%
Avg Volume (3M)5,063,770
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.29B | $1.53B | $453.5M | $417.4M | $448.3M |
| P/E | -14.23 | -6.51 | -1.81 | -2.55 | -2.79 |
| Price/Book | 52.51 | 75.63 | 10.83 | -11.35 | -31.88 |
| ROE | -369.11% | -1161.69% | -599.78% | 444.72% | 1142.68% |
| ROA | -94.45% | -169.57% | -146.63% | -160.52% | -124.75% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short47,547,517
Change from Prior Settlement+12.46%
% of Float—
Days to Cover (Short Ratio)7.38
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 6322.7% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +73.4%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -184.0%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-09-24; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PGEN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $55.0M | $23.3M | — | $856.0K | $1.3M | — | — | — |
| Operating income | $22.6M | -$6.0M | — | -$31.8M | -$22.6M | — | — | — |
| Net income | $20.1M | -$7.9M | -$146.3M | -$26.6M | -$54.2M | -$24.0M | -$58.8M | -$23.7M |
| EPS (diluted) | $0.05 | $-0.02 | $-1.06 | $-0.09 | $-0.18 | $-0.09 | $-0.23 | $-0.10 |
| EPS (basic) | $0.06 | $-0.02 | $-1.06 | $-0.09 | $-0.18 | $-0.09 | $-0.23 | $-0.10 |
| Operating margin | $41 | -$26 | — | -$3.7K | -$1.7K | — | — | — |
| Net margin | $37 | -$34 | — | -$3.1K | -$4.0K | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $170.3M | $138.6M | $155.5M | $171.3M | $101.9M | $128.8M | $145.3M | $83.5M |
| Total liabilities | $126.7M | $118.4M | $134.6M | $129.4M | $107.8M | $113.3M | $78.5M | $28.1M |
| Stockholders' equity | $43.6M | $20.2M | $20.9M | $41.9M | -$36.8M | -$14.1M | $38.5M | $55.4M |
| Total current assets | $134.4M | $101.7M | $115.2M | $129.6M | $62.8M | $84.6M | $102.4M | $34.5M |
| Total current liabilities | $29.4M | $21.1M | $37.3M | $32.1M | $23.2M | $24.0M | $21.5M | $21.2M |
| Cash & equivalents | $16.3M | $7.5M | $30.2M | $14.3M | $13.8M | $6.1M | $29.5M | $24.7M |
| Marketable securities (current) | $21.9M | $48.8M | $67.6M | $106.8M | $46.0M | $74.2M | $68.4M | $3.9M |
| Accounts receivable | $71.9M | $26.4M | $3.9M | $580.0K | $327.0K | $751.0K | $926.0K | $479.0K |
| Property, plant & equipment | $12.8M | $13.2M | $13.8M | $14.8M | $14.7M | $14.7M | $13.8M | $13.5M |
| Goodwill | $15.2M | $15.2M | $15.2M | $15.2M | $15.2M | $19.1M | $19.1M | $24.9M |
| Intangible assets | $2.5M | $2.9M | $3.2M | $3.5M | $3.8M | $4.1M | $4.5M | $4.8M |
| Other non-current assets | $708.0K | $782.0K | $908.0K | $753.0K | $590.0K | $427.0K | $371.0K | $425.0K |
| Accounts payable | $5.3M | $2.6M | $12.0M | $6.3M | $3.9M | $3.1M | $3.5M | $4.3M |
| Deferred revenue (current) | $284.0K | $410.0K | $517.0K | $480.0K | $413.0K | $549.0K | $589.0K | $407.0K |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | $93.9M | $93.5M | $93.2M | — | — | — | $0 | — |
| Other non-current liabilities | $77.0K | $106.0K | $134.0K | $163.0K | — | — | $0 | — |
| Retained earnings | -$2.33B | -$2.35B | -$2.34B | -$2.32B | -$2.17B | -$2.14B | -$2.09B | -$2.07B |
| Accumulated other comprehensive income (loss) | -$29.0K | -$17.0K | $7.0K | $24.0K | $11.0K | $12.0K | $12.0K | $13.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.8M | -$43.8M | -$23.5M | -$29.1M | -$19.0M | -$16.3M | -$8.2M | -$22.7M |
| Investing cash flow | $26.7M | $21.0M | $39.9M | -$63.4M | $28.4M | -$6.5M | -$65.4M | $5.7M |
| Financing cash flow | -$33.0K | $109.0K | -$514.0K | $93.0M | -$1.8M | -$679.0K | $78.4M | $32.1M |
| Free cash flow | -$18.2M | -$44.1M | -$23.5M | -$29.5M | -$19.9M | -$16.9M | -$9.3M | -$23.6M |
| Capital expenditures | $392.0K | $258.0K | $18.0K | $389.0K | $966.0K | $622.0K | $1.0M | $882.0K |
| Depreciation & amortization | $1.1M | $1.1M | $1.1M | $803.0K | $630.0K | $629.0K | $661.0K | $674.0K |
| Share-based compensation | $3.6M | $3.0M | $2.2M | $4.4M | $1.6M | $2.7M | $2.9M | $2.1M |
| Deferred income taxes | — | — | $0 | $0 | $0 | $0 | -$89.0K | $12.0K |
| Change in accounts receivable | $45.5M | $22.5M | $3.3M | $253.0K | -$424.0K | -$175.0K | $447.0K | -$32.0K |
| Change in inventory | $5.8M | $4.9M | $6.3M | $2.9M | $0 | $0 | $0 | $0 |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $47.7M | $33.9M | $23.9M | $145.3M | $28.5M | $10.4M | $112.4M | $23.2M |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Debt issued | — | — | -$654.0K | $93.5M | — | — | $0 | $0 |
| Debt repaid | — | — | $0 | — | — | — | $0 | $0 |
| Tax withholding on stock comp | $1.3M | $146.0K | $0 | $0 | $1.3M | $474.0K | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $9.7M | $3.9M | $6.2M | $26.9M | $14.3M |
| Operating income | -$110.5M | -$135.0M | -$99.8M | — | — |
| Net income | -$250.6M | -$126.2M | -$95.9M | $28.3M | -$92.2M |
| EPS (diluted) | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 |
| EPS (basic) | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 |
| Operating margin | -$1.1K | -$3.4K | -$1.6K | — | — |
| Net margin | -$2.6K | -$3.2K | -$1.5K | $105 | -$646 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $155.5M | $145.3M | $151.0M | $216.0M | $359.9M |
| Total liabilities | $134.6M | $78.5M | $32.5M | $89.7M | $252.5M |
| Stockholders' equity | $20.9M | $38.5M | $118.5M | $126.3M | $107.3M |
| Total current assets | $115.2M | $102.4M | $68.8M | $118.2M | $156.6M |
| Total current liabilities | $37.3M | $21.5M | $23.0M | $78.6M | $34.6M |
| Cash & equivalents | $30.2M | $29.5M | $7.6M | $4.9M | $36.4M |
| Marketable securities (current) | $67.6M | $68.4M | $55.3M | $51.1M | $72.2M |
| Accounts receivable | $3.9M | $926.0K | $902.0K | $978.0K | $1.3M |
| Property, plant & equipment | $13.8M | $13.8M | $7.1M | $7.3M | $8.6M |
| Goodwill | $15.2M | $19.1M | $26.6M | $36.9M | $37.6M |
| Intangible assets | $3.2M | $4.5M | $40.7M | $44.5M | $52.3M |
| Other non-current assets | $908.0K | $371.0K | $767.0K | $1.0M | $936.0K |
| Accounts payable | $12.0M | $3.5M | $1.7M | $4.1M | $3.1M |
| Deferred revenue (current) | $517.0K | $589.0K | $509.0K | $25.0K | $1.5M |
| Short-term debt | — | — | $0 | $43.2M | — |
| Long-term debt | $93.2M | $0 | — | $0 | $179.9M |
| Other non-current liabilities | $134.0K | $0 | — | — | $50.0K |
| Retained earnings | -$2.34B | -$2.09B | -$1.96B | -$1.87B | -$1.92B |
| Accumulated other comprehensive income (loss) | $7.0K | $12.0K | -$1.9M | -$3.5M | $203.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$87.8M | -$68.2M | -$66.9M | -$65.0M | -$55.8M |
| Investing cash flow | -$1.5M | -$20.7M | -$3.1M | $226.4M | -$74.5M |
| Financing cash flow | $90.0M | $110.6M | $29.6M | -$155.3M | $121.2M |
| Free cash flow | -$89.8M | -$76.8M | -$68.5M | -$70.0M | -$63.0M |
| Capital expenditures | $2.0M | $8.6M | $1.5M | $4.9M | $7.2M |
| Depreciation & amortization | $3.2M | $4.5M | $6.7M | $10.8M | $13.8M |
| Share-based compensation | $10.9M | $9.5M | $9.9M | $10.2M | $13.9M |
| Deferred income taxes | $0 | -$1.8M | -$479.0K | -$150.0K | -$167.0K |
| Change in accounts receivable | $3.0M | $24.0K | -$76.0K | $2.2M | $6.2M |
| Change in inventory | $9.2M | $0 | $0 | -$2.3M | $1.9M |
| Change in accounts payable | — | — | — | — | — |
| Purchases of investments | $208.0M | $187.2M | $185.0M | $0 | $174.2M |
| Debt issued | $92.8M | $0 | $0 | — | $0 |
| Debt repaid | $0 | $0 | $43.2M | $155.3M | $466.0K |
| Tax withholding on stock comp | $1.8M | $0 | $0 | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PGEN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-23 to 2026-09-23
Recent transactions
- Insiders have net sold 1,330,266 shares over the last 182 days, across 1 purchase and 16 sales.
- Most recent: Thomasian Harry Jr. (Chief Financial Officer) — Option exercise of 10,744 shares on 2026-09-23.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)3,411 sh(1 txns)
Sales (open market)1,333,677 sh(16 txns)
Net Shares-1,330,266
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Thomasian Harry Jr. | Chief Financial Officer | Option exercise | 2026-09-23 | 10,744 |
| KINDLER JEFFREY B | Director | Open market sale | 2026-08-26 | 185,000 |
| Shah Rutul R | Chief Operating Officer | Option exercise | 2026-08-25 | 15,342 |
| Tennant Phil | Chief Commercial Officer | Option exercise | 2026-08-25 | 79,166 |
| Lehr Donald P. | Chief Legal Officer | Option exercise | 2026-08-23 | 5,208 |
| Sabzevari Helen | President and CEO | Option exercise | 2026-08-23 | 20,833 |
| AGEE NANCY H | Director | Open market purchase | 2026-08-21 | 3,411 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-23 | Thomasian Harry Jr. | Chief Financial Officer | Option exercise | 10,744 | $4.72 |
| 2026-09-23 | Thomasian Harry Jr. | Chief Financial Officer | Option exercise | 42,918 | $2.33 |
| 2026-09-23 | Thomasian Harry Jr. | Chief Financial Officer | Option exercise | 2 | $0.96 |
| 2026-09-23 | Thomasian Harry Jr. | Chief Financial Officer | Option exercise | 1 | $1.21 |
| 2026-08-26 | KINDLER JEFFREY B | Director | Open market sale | 185,000 | $7.44 |
| 2026-08-25 | Shah Rutul R | Chief Operating Officer | Option exercise | 15,342 | $2.33 |
| 2026-08-25 | Shah Rutul R | Chief Operating Officer | Open market sale | 15,342 | $7.50 |
| 2026-08-25 | Tennant Phil | Chief Commercial Officer | Option exercise | 79,166 | $1.61 |
| 2026-08-25 | Tennant Phil | Chief Commercial Officer | Open market sale | 79,166 | $7.50 |
| 2026-08-23 | Lehr Donald P. | Chief Legal Officer | Option exercise | 5,208 | — |
| 2026-08-23 | Lehr Donald P. | Chief Legal Officer | Tax withholding | 2,488 | $7.20 |
| 2026-08-23 | Thomasian Harry Jr. | Chief Financial Officer | Option exercise | 7,291 | — |
| 2026-08-23 | Thomasian Harry Jr. | Chief Financial Officer | Tax withholding | 3,577 | $7.20 |
| 2026-08-23 | Shah Rutul R | Chief Operating Officer | Option exercise | 7,500 | — |
| 2026-08-23 | Shah Rutul R | Chief Operating Officer | Tax withholding | 3,647 | $7.20 |
| 2026-08-23 | Tennant Phil | Chief Commercial Officer | Option exercise | 5,208 | — |
| 2026-08-23 | Tennant Phil | Chief Commercial Officer | Tax withholding | 2,585 | $7.20 |
| 2026-08-23 | Sabzevari Helen | President and CEO | Option exercise | 20,833 | — |
| 2026-08-23 | Sabzevari Helen | President and CEO | Tax withholding | 10,184 | $7.20 |
| 2026-08-21 | AGEE NANCY H | Director | Open market purchase | 3,411 | $7.23 |
| 2026-08-21 | Shah Rutul R | Chief Operating Officer | Option exercise | 34,658 | $2.33 |
| 2026-08-21 | Shah Rutul R | Chief Operating Officer | Open market sale | 34,658 | $7.50 |
| 2026-08-06 | Shah Rutul R | Chief Operating Officer | Open market sale | 32,739 | $6.86 |
| 2026-08-03 | Shah Rutul R | Chief Operating Officer | Option exercise | 33,772 | $2.33 |
| 2026-08-03 | Shah Rutul R | Chief Operating Officer | Open market sale | 33,772 | $6.50 |
| 2026-07-31 | Thomasian Harry Jr. | Chief Financial Officer | Open market sale | 100,000 | $6.06 |
| 2026-07-01 | Thomasian Harry Jr. | Chief Financial Officer | Open market sale | 171,429 | $5.53 |
| 2026-06-29 | Thomasian Harry Jr. | Chief Financial Officer | Open market sale | 28,571 | $5.78 |
| 2026-06-29 | Shah Rutul R | Chief Operating Officer | Option exercise | 42,924 | $2.33 |
| 2026-06-29 | Shah Rutul R | Chief Operating Officer | Open market sale | 42,924 | $5.85 |
| 2026-06-29 | Sabzevari Helen | President and CEO | Option exercise | 346,836 | $2.33 |
| 2026-06-29 | Sabzevari Helen | President and CEO | Open market sale | 346,836 | $5.89 |
| 2026-05-28 | Thomasian Harry Jr. | Chief Financial Officer | Open market sale | 41,884 | $4.36 |
| 2026-05-28 | Tennant Phil | Chief Commercial Officer | Open market sale | 30,272 | $4.36 |
| 2026-05-28 | Shah Rutul R | Chief Operating Officer | Open market sale | 42,703 | $4.36 |
| 2026-05-28 | Lehr Donald P. | Chief Legal Officer | Open market sale | 29,131 | $4.36 |
| 2026-05-28 | Sabzevari Helen | President and CEO | Open market sale | 119,250 | $4.36 |
| 2026-05-23 | Thomasian Harry Jr. | Chief Financial Officer | Option exercise | 87,500 | — |
| 2026-05-23 | Tennant Phil | Chief Commercial Officer | Option exercise | 62,500 | — |
| 2026-05-23 | Shah Rutul R | Chief Operating Officer | Option exercise | 90,000 | — |
| 2026-05-23 | Sabzevari Helen | President and CEO | Option exercise | 250,000 | — |
| 2026-05-23 | Lehr Donald P. | Chief Legal Officer | Option exercise | 62,500 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:03 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-24 | 4 | 2026-09-23 | View on SEC.gov → |
| 2026-08-28 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-21 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-23 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-23 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-21 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-23 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-23 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-08-03 | View on SEC.gov → |
Recent news
Headlines about PGEN (Precigen, Inc.). Links open the publisher — we don’t host full articles.
-
Precigen, Inc. (PGEN) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-21 -
Precigen (PGEN) Stock May Be Fully Priced On Its Huge 3 Year Run
Yahoo · 2026-10-20 -
(PGEN) Volatility Zones as Tactical Triggers
Stock Traders Daily · 2026-10-18 -
Precigen (PGEN): Commercial Launch Success Validates Early Capital Raise Thesis
Yahoo · 2026-10-12 -
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Yahoo Finance · 2026-10-05 -
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
Yahoo Finance · 2026-10-05 -
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Yahoo Finance · 2026-10-05 -
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
Yahoo Finance · 2026-10-05
No headlines in this category right now — try “All”.